



HAL
open science

Impact of Polylactide Fluorinated End-Group Lengths and Their Dynamics on Perfluorohexane Microcapsule Morphology

Guilherme Picheth, Laurence Moine, Sophie Houvenagel, Leociley Menezes, Guilherme L Sasaki, Camille Dejean, Nicolas Huang, Rilton Alves de Freitas, Nicolas Tsapis

► **To cite this version:**

Guilherme Picheth, Laurence Moine, Sophie Houvenagel, Leociley Menezes, Guilherme L Sasaki, et al.. Impact of Polylactide Fluorinated End-Group Lengths and Their Dynamics on Perfluorohexane Microcapsule Morphology. *Macromolecules*, 2019, 52 (6), pp.2589-2596. 10.1021/acs.macromol.9b00217 . hal-02323672

HAL Id: hal-02323672

<https://hal.science/hal-02323672v1>

Submitted on 22 Oct 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Impact of polylactide fluorinated-end group length and their dynamics on
perfluohexane microcapsules morphology**

Guilherme F. Picheth^{a,c}, Laurence Moine^{a*}, Sophie Houvenagel^a, Leociley R. A. Menezes^d,
Guilherme L. Sasaki^d, Camille Dejean^b, Nicolas Huang^a, Rilton Alves de Freitas^c, Nicolas
Tsapis^{a*}

^a Institut Galien Paris-Sud, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.

^b BioCIS, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry, France.


^c Biopol, Chemistry Department, Federal University of Paraná, 81531-908 Curitiba, PR, Brazil.

^d NMR Center, Federal University of Paraná, 81531-980. Curitiba, PR, Brazil.

* Corresponding authors at: Institut Galien Paris-Sud, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92296 Châtenay-Malabry. E-mail address: laurence.moine@u-psud.fr (Laurence Moine), nicolas.tsapis@u-psud.fr (Nicolas Tsapis).

Keywords: Perfluorocarbon microcapsules, perfluorohexane, fluorinated polymers, focused ultrasound, end-group dynamics, fluorous interaction

Table of Content Graphic



1 **Abstract**

2 We have synthesized polylactide (PLA) polymers containing five distinct lengths of
3 fluorinated end-groups (from C_3F_7 to $C_{13}F_{27}$). The influence of fluorinated end-groups length
4 and their dynamics in chlorinated solvents (chloroform and dichloromethane) was
5 investigated as a function of the presence of perfluorohexane (PFH) and related to the
6 morphology of capsules of PFH obtained using these fluorinated polylactides. ^{19}F spin-spin
7 relaxation time (T_2) measurements revealed a reduced mobility of the fluorinated units with
8 dependency on fluorinated chain length in the order $C_3F_7 > C_8F_{17} > C_{13}F_{27}$. The presence of
9 perfluorohexane (PFH) led to a further decrease on the segmental mobility, indicating the
10 existence of fluororous interactions. The T_2 relaxation time of the CF_3 resonance of PLA- C_3F_7
11 decreased from 540 ± 50 ms in $CDCl_3$ to 81 ± 15 ms after the addition of PFH. Due to these
12 fluororous interactions, PLA polymers containing short fluorinated groups (C_3F_7 and C_6F_{13}) led
13 to microcapsules with core-shell morphologies, whereas those formulated with long F-units
14 (C_8F_{17} , $C_{11}F_{23}$ and $C_{13}F_{27}$) favored the formation of multinucleated capsules as observed by
15 confocal microscopy.

16

17

18

19

20

21

22 **1. Introduction**

23 Fully and partly fluorinated compounds are widely explored in the chemical industry and
24 academic research for their inherent immiscibility with hydrophobic and lipophobic solvents.
25 This so-called “fluorophilic” character is responsible for low or “gas like” intermolecular
26 attractions which confer to such molecules inertness and biocompatibility, features that
27 attracted special attention for a wide range of biomedical applications^{1,2}. In particular, liquid
28 perfluorocarbons (PFCs), such as perfluorohexane (PFH) or perfluorooctyl bromide (PFOB)
29 are described to be minimally absorbed, eliminated from the lungs by evaporation and did
30 not lead to any significant histological, cellular or biochemical disturbance³. Therefore, these
31 PFCs are intensively investigated for their potential to act as intravascular contrast agents⁴.

32 Recent reports describe the use of capsules containing PFOB to provide *in vivo* ¹⁹F-MRI or
33 ultrasound detection and also passively deliver chemotherapeutics to cancer cells⁵⁻⁹. Similar
34 formulations use PFH as an active core for its lower boiling point, as it favors liquid-to-gas
35 transition by acoustic and thermal stimuli, allowing real-time ultrasonic imaging as well as
36 localized drug-release¹⁰⁻¹². Nonetheless, the entrapment of fully fluorinated PFCs, such as
37 PFH, within a polymeric shell is proving to be difficult due to their dual lipophobic and
38 hydrophobic character and their trend to easily evaporate during formulation¹⁴. Several
39 groups have turned to the use of fluorinated surfactants or lipids to improve PFCs
40 encapsulation¹⁵⁻¹⁷. Literature also reports the functionalization of polymer with fluorinated
41 end-groups to favor interactions with PFCs^{11,14,18-24}. It was previously demonstrated that a
42 wide range of fluorinated end-groups linked to the PLA chain – from C₃F₇ to C₁₃F₂₇ –
43 increased the entrapment of PFCs into nanocapsules, resulting in more efficient acoustic
44 responses^{14,19}. However, no significant distinction regarding the morphology or PFC
45 entrapment was observed by increasing the length of the end-fluorinated groups in
46 nanoformulations.

47 The main objective of this study is to investigate deeper the influence and extent of fluorous
48 interactions between fluorinated end-groups of PLA-C_xF_{2x+1} and PFH on the final morphology
49 of microcapsules (MC) as a function of fluorinated end-group length. In particular, we
50 examine the role of the solvent in which the polymer was dissolved on the strength of
51 fluorous interactions by comparing chloroform and dichloromethane, two solvents often used
52 to formulate polymer particles and capsules^{25,26}. To fully explore the impact of fluorinated
53 end-group chain length and solvent, end-group dynamics and PFH entrapment efficiency
54 were evaluated by NMR and MC morphology was assessed by confocal microscopy. This
55 study provides information for the morphological design of new ultrasound activable systems
56 formulated with fluorinated PLA polymers.

57

58 **2. Materials and Methods**

59 **2.1 Materials**

60 D,L-lactide was purchased from Polysciences (Germany) and perfluorohexane 98+% was
61 acquired from Alfa Aesar (Germany). 1-hexanol was obtained from Acros Organics
62 (Belgium), 2,2,3,3,4,4-heptafluoro-1-butanol, 1H,1H perfluoro-1-heptanol, 1H,1H perfluoro-1-
63 nonanol, 1H,1H perfluoro-1-dodecanol and 1H,1H perfluoro-1-tetradecanol were acquired
64 from Fluorochem (United Kingdom). Acetone, tetrahydrofuran (THF) and dichloromethane
65 were purchased from Carlo Erba Reactifs (France), chloroform and diethyl ether from VWR
66 (France). Nile red, stannous octoate, sodium cholate, trifluoroacetic acid (TFA), deuterated
67 chloroform and deuterated dichloromethane were provided by Sigma-Aldrich (France). The
68 ultrapure water was produced by a RIOS/Milli-Q system (Millipore, France), with a resistivity
69 of 18.2 MΩcm. The NMR sample tubes and coaxial inserts were obtained from CortecNet
70 (France).

71 **2.2 Polymer Synthesis**

72 All fluorinated (PLA-C₃F₇, PLA-C₆F₁₃, PLA-C₈F₁₇, PLA-C₁₁F₂₃ and PLA-C₁₃F₂₇) and non-
73 fluorinated (PLA-C₆H₁₃) derivatives of polylactide polymers were synthesized by ring opening
74 polymerization (ROP) with the presence of stannous octoate as catalyst^{27,28}. All glassware
75 and stir bars were flame-dried and cooled under argon flow. Briefly, in a 10 mL schlenck tube
76 equipped with a magnetic stir-bar, the D,L-lactide (10.4 mmol, 1.5 g) and corresponding
77 initiator (0.075 mmol) – 1-hexanol for PLA-C₆H₁₃, 2,2,3,3,4,4-heptafluoro-1-butanol for PLA-
78 C₃F₇, 1H,1H perfluoro-1-heptanol for PLA-C₆F₁₃, 1H,1H perfluoro-1-nonanol for PLA-C₈F₁₇,
79 1H,1H perfluoro-1-dodecanol for PLA-C₁₁F₂₃ or 1H,1H perfluoro-1-tetradecanol for PLA-
80 C₁₃F₂₇ – were added to the flask under argon flow. The tube was sealed with a rubber cap
81 and a stannous octoate solution (0.05 mmol, 20 mg) dissolved in 2 mL of dried toluene was
82 added through the septum. The tube was purged with argon for 0.5 h and the polymerization
83 reaction was conducted with continuous stirring at 130 °C for 55 minutes in an oil bath under

84 argon flow. The reaction was quenched by immersing the flask in a cold water bath.
85 Afterwards, the solvent was evaporated under reduced pressure for 1h and the material was
86 dissolved in 5 mL of chloroform. The product was purified by precipitation as previously
87 described²⁹: all polymers were precipitated into cold diethyl ether (80 mL), next, PLA-C₆H₁₃
88 was dissolved into THF (5 mL), whereas the fluorinated polymers were dissolved in acetone
89 (20 mL) and precipitated again in ultrapure water (150 mL). The samples were freeze-dried
90 for 24 h and a white powder was obtained. Lactide conversion $\geq 95\%$ (¹H-NMR). ¹H-NMR
91 [400 MHz, CDCl₃, 25°C] **PLA-C₆H₁₃**: δ_{H} 5.10-5.28 (PLA-CHCH₃COO-), 1.52-1.61 (PLA-
92 CHCH₃COO-), 0.88-0.92 (-CH₂CH₃). **PLA-C₃F₇**, **PLA-C₆F₁₃**, **PLA-C₈F₁₇**, **PLA-C₁₁F₂₃** and
93 **PLA-C₁₃F₂₇**: δ_{H} 5.10-5.28 (PLA-CHCH₃COO-), 4.50-4.70 (-OCH₂CF₂-), 1.52-1.61 (PLA-
94 CHCH₃COO-). ¹⁹F-NMR [400 MHz, CDCl₃, 25°C] **PLA-C₃F₇**: δ_{F} -79.0 (-CF₃), -118.7 (-
95 OCH₂CF₂-) and -125.7 (-CF₂CF₃); **PLA-C₆F₁₃**, **PLA-C₈F₁₇**, **PLA-C₁₁F₂₃** and **PLA-C₁₃F₂₇**: δ_{F} -
96 78.9 (-CF₃), -117.7 (-OCH₂CF₂-), -120.0 (-CF₂)_nCF₂CF₃, -120.7 (-OCH₂CF₂CF₂CF₂-), -121.4
97 (-OCH₂CF₂CF₂-) and -124.2 (-CF₂CF₃).

98 **2.3 Characterization**

99 All polymers were characterized by size exclusion chromatography (SEC) in chloroform at 30
100 °C with a flow rate of 1 mL.min⁻¹ by two columns (PL-gel 5 μ m MIXED-D 300 x 7.5 mm)
101 calibrated against a curve based on poly(methyl methacrylate) standards (PMMA, Polymer
102 Laboratories, Varian Inc.) The system was coupled to a refractive index detector
103 (Spectrasystem RI-150, Thermo Electro Corp.). ¹H and ¹⁹F-NMR spectra were obtained on a
104 Bruker AVANCE III HD 400 MHz in CDCl₃ at 25°C.

105 **2.4 Interfacial surface tension**

106 The interfacial surface tension was performed in a Tracker tensiometer (Teclis,
107 France). PFH was previously filtrated by a column of aluminum oxide. A constant 2 μ L PFH
108 or sodium cholate drop was formed by a syringe and a G20 stainless steel needle inside an
109 optical glass cuvette containing fixed polymer concentrations of 25 mg.mL⁻¹ in chloroform or

110 dichloromethane previously filtered by 0.22 μm (Millipore). The temperature was kept at 20
111 $^{\circ}\text{C}$ and the interfacial surface tension was determined from the drop profile employing the
112 Laplace equation and the forces balance between capillarity and gravity.

113 **2.5 ^{19}F -NMR T_1 and T_2 Relaxation**

114 ^{19}F Spin-lattice and spin-spin relaxation measurements were performed at 25 $^{\circ}\text{C}$ in CDCl_3 or
115 CD_2Cl_2 with fixed polymer concentrations of 25 $\text{mg}\cdot\text{mL}^{-1}$. Samples containing 15 μL of PFH
116 were also evaluated. The samples were not degassed. All experiments were performed on a
117 Bruker AVANCE III HD NMR spectrometer operating at 9.4 T, equipped with a 5-mm
118 multinuclear inverse detection probe, observing ^{19}F and ^1H nuclei at 376.49 and 400.13 MHz,
119 respectively. ^{19}F T_1 was determined by the inversion-recovery pulse sequence ($T_1\text{IR}$). The
120 delay (τ) between the inversion and read-pulse was varied along 16 values (1 to 22 s). The
121 total number of scans was 32, spectral width = 100 ppm and relaxation delay = 22 s. ^{19}F T_2
122 values were measured by the PROJECT-CPMG pulse sequence along 15 values of τ (0.1 to
123 2 ms)³⁰. The number of scans was 128, spectral width = 100 ppm and relaxation delay = 10
124 s. Relaxation times were obtained by nonlinear least-squares fitting of a mono- exponential
125 function with $r^2 \geq 0.998$ for all samples.

126

127 **2.6 Microcapsules Formulation**

128 Microcapsules were prepared by the emulsion-evaporation technique, as previously
129 described¹³, with minor modifications. Briefly, the desired amount of polymer was dissolved
130 into 2 mL of chloroform or dichloromethane in a 50 mL glass flask. Afterwards, 50 μL of Nile
131 red (55 $\mu\text{g}\cdot\text{mL}^{-1}$) was added and the flask was sealed with a rubber cap. Next, 30 μL of PFH
132 was introduced through the septum with constant stirring and the media was emulsified with
133 10 mL of sodium cholate 1.5% (w/w) at 4 $^{\circ}\text{C}$. The mixture was submitted to high-speed
134 homogenization at 8.000 RPM using an Ultra-Turrax T25 (IKA) coupled with an SN25-10G
135 dispersing tool in an ice bath for 1 minute. The solvent was removed by rotary evaporation

136 (Büchi) with a 30 °C water bath and recirculation chiller at -10 °C. A vacuum gradient from
137 400 to 30 mbar in 7 steps of 5 minutes was employed. Afterwards, the total volume of each
138 sample was completed to 10 mL with ultrapure water.

139 **2.7 Confocal Microscopy**

140 Microcapsules were washed twice with ultrapure water by centrifugation and resuspended in
141 glycerol to minimize motion. All samples were observed in a Leica TCS SP5 confocal
142 scanning microscope (Leica) with a 1 mW helium neon laser operating at excitation of 551
143 nm and 636 nm of emission, Plan Achromat 63X objective (NA 1.40 oil immersion) and
144 pinhole diameter at 71 nm. For diameter analysis, the measurements were performed in the
145 equatorial plane of each capsule as previously described ¹³.

146 **2.8 Scanning Electron Microscopy**

147 Scanning electron microscopy was performed in a Merlin 6040 (Carl Zeiss, Germany)
148 operating at 3 kV. All microcapsules were washed twice with ultrapure water by
149 centrifugation to remove the excess of sodium cholate, deposited on carbon conductive
150 double-sided tape (Euro-medex, France) and dried at room temperature. Afterwards, they
151 were coated with a palladium–platinum layer of about 3 nm using a Cressington sputter-
152 coater 208HR with a rotary-planetary-tilt stage, fitted with an MTM-20 thickness controller.

153 **2.9 PFH encapsulation efficiency by ¹⁹F-NMR spectroscopy**

154 For PFH quantification, 1 mL of microcapsules was freeze-dried during 24 h employing an
155 Alpha-1-2 LD apparatus (Christ). The flasks were hermetically sealed with a rubber cap and
156 stored at -20 °C until analysis. The PFH encapsulation efficiency was determined as
157 described by Diou *et al.* ²⁹. A total volume of 1 mL of chloroform was introduced into the
158 sealed tube by a needle, the suspension was vortexed (5 cycles of 30 seconds) and
159 centrifuged at 0 °C for 10 minutes at 5000 rpm (Jouan CR4I centrifuge, Thermo Electron
160 Corporation). The organic solution was collected in a cold room at 4 °C and introduced into

161 an NMR tube that was afterwards loaded with a stem coaxial insert containing TFA in D₂O
162 (12 μmol.mL⁻¹) as external standard ³¹. All spectra were obtained at 4 °C on a Bruker Avance
163 300 (400 MHz) spectrometer. The total amount of encapsulated PFH was determined based
164 on a PFH calibration curve. For each MC sample, the integration of the TFA peak at -76.5
165 ppm was determined as 3 and the resulting integration of the PFH CF₃ at -81.2 ppm was
166 used to calculate the PFH concentration in the NMR tube based to the equation of the
167 calibration curve.

168 **2.10 Statistical analysis**

169 The statistical analysis was performed using Statistica™ 8.0 software (StatSoft Inc., Tulsa,
170 USA). The data was analyzed by two-sided Student's *t*-test and a statistical significance was
171 set at the level of $p < 0.05$.

172 **3. Results and Discussion**

173 **3.1 Polymers synthesis and characterization**

174 Six end-group fluorinated or alkylated polymers were synthesized by ring opening
175 polymerization of D,L-lactide with appropriate initiator (hexanol or fluorinated alcohols) as
176 previously described^{14,19,28,32} (reaction yield > 85%). The polylactide main chain is
177 constituted by ~140 repetitive units containing different lengths of end fluorinated-groups:
178 polymers are designated according to the terminal group chemistry and length of fluorinated
179 units as PLA-C₆H₁₃, PLA-C₃F₇, PLA-C₆F₁₃, PLA-C₈F₁₇, PLA-C₁₁F₂₃ and PLA-C₁₃F₂₇. They
180 were characterized by ¹H and ¹⁹F-NMR and exhibited a molecular weight around 18000-
181 21000 g.mol⁻¹ as assessed by NMR, with a narrow dispersity (Supporting information **Figure**
182 **S1 and Table S1**).

183 **3.2 Polymers dynamics**

184 To explore the role and extent of fluorous interactions between the different PLA-C_xF_{2x+1} and
185 PFH during the formation of microcapsules, we have investigated interfacial properties,
186 dynamics in solution as well as morphological features generated by each of these polymers.
187 As fluorine recognition and compartmentalization are strictly dependent on the solvent's
188 character, the behavior and impact of polymer end-group chemistry was studied in two
189 distinct solvents usually employed in the formulation of MC, namely, chloroform and
190 dichloromethane^{25,26}.

191 The interfacial activity of the polymers was determined at the solvent/PFH and
192 solvent/sodium cholate (SC) interfaces by interfacial surface tension measurements (**Table**
193 **1**). At the solvent/SC interface, interfacial tension values were between 7–8 mN.m⁻¹ in CHCl₃
194 or CH₂Cl₂, for all polymers, suggesting no specific solvent or end-group contribution to the
195 interfacial activity. At the PFH/solvent interface, polymers dissolved in CHCl₃ exhibited an
196 interfacial tension average value of 3.0±0.05 mN.m⁻¹ whereas 6.0±0.1 mN.m⁻¹ was measured
197 for polymers dissolved in CH₂Cl₂, indicating that CHCl₃ favors PFH spreading. Nonetheless,

198 none of the polymers was able to decrease the interfacial tension compared to the solvent
 199 itself regardless the end-group chemistry or the length of the fluorinated end-group.

200 **Table 1.** Interfacial tensions at the perfluorohexane/solvent and alkylated or fluorinated
 201 polymer/sodium cholate 1.5% (w/v) interfaces. All polymers were dissolved at 25 mg.mL⁻¹ in
 202 chloroform or dichloromethane. All results are expressed in mN.m⁻¹.

	Chloroform		Dichloromethane	
	PFH/solvent	Solvent/SC 1.5%	PFH/solvent	Solvent/SC 1.5%
Solvent	3.2±0.3	7.5±0.3	6.0±0.3	8.1±0.2
PLA-C₆H₁₃	3.0±0.5	7.5±0.2	6.2±0.5	8.0±0.2
PLA-C₃F₇	3.0±0.3	7.0±0.1	6.1±0.7	7.5±0.3
PLA-C₆F₁₃	3.0±0.5	7.1±0.5	6.2±0.4	7.7±0.5
PLA-C₈F₁₇	3.1±0.4	7.1±0.2	5.9±0.4	7.7±0.4
PLA-C₁₁F₂₃	3.0±0.3	7.2±0.3	5.9±0.3	7.8±0.2
PLA-C₁₃F₂₇	3.1±0.4	7.4±0.1	6.1±0.4	7.6±0.1

203 PFH-SC (1.5% w/v) interfacial tension was 22.5±0.2 mN.m⁻¹


204 The lack of adsorption at the PFH/solvent interface might be explained by the mass ratio
 205 difference between the relatively small fluorinated blocks compared to the PLA main chain
 206 (C₃ to C₁₃ for fluorinated block vs. 140 repetitive units for PLA) and the conformation
 207 assumed by the polymer in solution. Indeed, as the PLA polymers are well solvated in CHCl₃
 208 and CH₂Cl₂ (Hildebrand solubility parameter (δ_T) of 20.8 MPa^{0.5} for unmodified PLA, 18.7
 209 MPa^{0.5} for CHCl₃ and 20.2 MPa^{0.5} for CH₂Cl₂³³), a conformational rearrangement based on
 210 the higher solubility of the polymeric chains within the solvents may hide the fluorinated
 211 groups inside the PLA coil, hindering an effective interaction with the PFH phase¹⁹.

212 Although no interfacial activity was observed at the PFH/solvent interface during static
 213 measurements, the solvent-evaporation process is dynamic and associated with transitory
 214 interfacial instabilities due to system disorganization³⁴. Such constant rearrangement of
 215 water and organic solvent molecules may promote the formation of fluorinated domains

216 favorable for PFH encapsulation ³⁵. Indeed, many studies carried on mixed systems,
217 containing both fluorocarbons and organic solvents, showed the tendency of perfluoralkyl
218 moieties to self-associate and generate fluororous compartments. This aggregation in rich
219 fluororous domains is generally associated to a reduced mobility of fluorinated groups ^{26,36,37}.

220 To assess the behavior of the fluorinated chains in a more dynamic media containing PFH –
221 a situation similar to what happens prior to solvent evaporation – the end-group mobility of
222 three fluorinated polymers, PLA-C₃F₇, PLA-C₈F₁₇ and PLA-C₁₃F₂₇, was analyzed by fluorine
223 NMR spectroscopy employing spin-lattice (T₁) and spin-spin (T₂) relaxation measurements at
224 fixed polymer concentration of 25 mg.mL⁻¹ and 15 μL of PFH (corresponding to the
225 formulation conditions). Accordingly, the CF₃ group dynamics in each solvent was probed in
226 presence and absence of PFH in the solvent. Unfortunately, some of the PFH resonances
227 overlapped with the CF₃ polymer signals for PLA-C₈F₁₇ and PLA-C₁₃F₂₇ in both solvents. Only
228 PLA-C₃F₇ exhibited well segregated resonance from those of PFH because of the different
229 chemical environments, which permitted a resonance shift towards lower magnetic fields, not
230 overlapping with PFH as displayed in **Figure 1**. The nomenclature and ¹⁹F-NMR peak
231 labeling consists alphabetically with the position of the fluorinated resonance respective to
232 the PLA chain ^{38,39}.

233



234

235 **Figure 1.** Magnified CF_3 and CF_2 regions of the ^{19}F -NMR spectra for PLA- C_3F_7 , PLA- C_8F_{17}
 236 and PLA- $\text{C}_{13}\text{F}_{27}$ in CDCl_3 . The insets (left) exhibit the CF_3 resonance in a mixed system of
 237 polymer and perfluorohexane. ^{19}F peak assignment is indicated in the top of each image.

238 T_2 analysis revealed that the CF_3 resonance mobility decreased strongly for polymers
 239 functionalized with longer fluorinated units in the order $\text{C}_3\text{F}_7 > \text{C}_8\text{F}_{17} > \text{C}_{13}\text{F}_{27}$ for both solvents
 240 (**Table 2**). Such reduction in the local fluorine dynamics according to chain length is related
 241 to the strong electronegativity of the C-F bond that generates linear and rigid chain
 242 conformations, reducing the segmental mobility as the chain length increases⁴⁰.
 243 Nonetheless, samples dissolved in CDCl_3 showed smaller relaxation values compared to
 244 their counterparts prepared in CD_2Cl_2 : this effect is clearly illustrated by the CF_3 resonance of
 245 PLA- C_3F_7 , with T_2 of 540 ± 50 ms in CDCl_3 and 1530 ± 150 ms in CD_2Cl_2 . Such results were also
 246 confirmed by T_1 measurements (Supporting information **Table S2**). These significant
 247 changes in relaxation times indicate that chloroform is not a good solvent for the fluorinated
 248 end-groups and drives self-association of ^{19}F containing units.

249


250 **Table 2.** ^{19}F spin-spin relaxation (T_2) values of CF_3 resonances for samples dissolved in
 251 deuterated chloroform or dichloromethane in presence of absence of perfluorohexane. All
 252 polymers were dissolved at fixed concentration of 25 mg.mL^{-1} (Experiment performed in
 253 duplicate, $n=2$).

Sample	T_2 (ms)		T_2 (ms)	
	CDCl_3	CDCl_3+PFH	CD_2Cl_2	$\text{CD}_2\text{Cl}_2+\text{PFH}$
PLA- C_3F_7	540 ± 50	81 ± 15	1530 ± 150	1710 ± 250
PLA- C_8F_{17}	210 ± 20	---	1263 ± 165	---
PLA- $\text{C}_{13}\text{F}_{27}$	76 ± 10	---	790 ± 50	---

254

255 Afterwards, PFH was added to each polymer solution to simulate the system behavior just
 256 before emulsification with sodium cholate. In CD_2Cl_2 , T_2 varied from 1530 ± 150 ms to
 257 1710 ± 250 ms in presence of PFH, showing that the end-group dynamics is not significantly
 258 affected by PFH addition in the media ($p = 0.475$). However, in CDCl_3 , the CF_3 signal of PLA-
 259 C_3F_7 showed a significant T_2 decrease with PFH, from 540 ± 50 ms to 81 ± 15 ms ($p < 0.05$).
 260 This lower mobility denotes a polymer rearrangement in presence of PFH evidencing an
 261 increased tendency for the fluorinated segments to associate with each other (**Figure 2**).
 262 Indeed, in CHCl_3 , addition of PFH further decreases the solubility of the fluorinated segments
 263 which promotes dipolar interactions between the fluorinated end-group and PFH. These
 264 more efficient interactions in CHCl_3 suggest formation of F-rich domains where the reduced
 265 mobility of the fluorinated segment leads to shorter T_2 values.

266



267
 268 **Figure 2.** T_2 decay profiles for the CF_3 resonance of $\text{PLA-C}_3\text{F}_7$ in CDCl_3 (A) and CD_2Cl_2 (B)
 269 without (open circles) and with perfluorohexane (dark circles).

270 According to those results, the introduction of PFH was able to reduce the local end-
 271 fluorinated group mobility of $\text{PLA-C}_3\text{F}_7$ in CDCl_3 . As PFH is well dissolved in chloroform, its
 272 contact with the fluorinated units may lead to the formation of fluorophilic domains, a process
 273 that might also depends on the length of the fluorinated group. This scenario, however,
 274 illustrates the system's behavior only in stable organic solutions; during the solvent-
 275 evaporation process in which MCs are formulated, transitory and thermodynamically
 276 unstable interfaces are created. Therefore, the ability of each fluorinated derivative to better
 277 stabilize and retain PFH as a liquid core was further studied in MCs formulations.

278 **3.2 Solvent Influence on MC formulation**

279 The impact of the fluorinated end-groups on the final morphology of microcapsules was then
 280 studied for all synthesized polymers. All microcapsules were initially formulated with fixed
 281 amounts of polymer (50 mg) that were dissolved either in chloroform or dichloromethane and

282 subsequently submitted to the same solvent-evaporation process. The encapsulation
 283 efficiency (EE) of PFH was quantified in freeze-dried samples by ^{19}F -NMR and the size of all
 284 MCs was measured by confocal microscopy as listed in **Table 3**.

285 **Table 3.** Encapsulation efficiency and size of microcapsules formulated with 50 mg of
 286 polymer prepared in chloroform and dichloromethane.

Sample	Chloroform		Dichloromethane	
	Size (μm)*	PFH EE (%)	Size (μm)*	PFH EE (%)
PLA-C ₆ H ₁₃	4.2 \pm 1.0	5.5 \pm 0.2	4.8 \pm 0.8	12.3 \pm 0.2
PLA-C ₃ F ₇	4.4 \pm 0.6	10.1 \pm 0.2	4.7 \pm 0.8	9.1 \pm 0.1
PLA-C ₆ F ₁₃	4.8 \pm 1.0	12.7 \pm 0.2	4.6 \pm 1.0	13.1 \pm 1.3
PLA-C ₈ F ₁₇	4.6 \pm 0.8	10.3 \pm 0.5	4.9 \pm 1.2	11.1 \pm 0.2
PLA-C ₁₁ F ₂₃	5.2 \pm 1.4	11.1 \pm 1.4	4.8 \pm 0.9	7.1 \pm 0.1
PLA-C ₁₃ F ₂₇	5.2 \pm 1.0	11.4 \pm 1.5	5.3 \pm 0.6	10.0 \pm 0.7


287 *All measurements correspond to observation and analysis of at least 100 microcapsules per each group.

288 As determined by ^{19}F NMR, the non-fluorinated polymer, PLA-C₆H₁₃, presented an
 289 encapsulation efficiency of 5.5 \pm 0.1% when prepared in CHCl₃. The use of fluorinated
 290 polymers led to a 2-fold increase in PFH encapsulation efficiency, reaching 11 \pm 3.0% without
 291 any significant distinction as a function of the fluorinated end-group length (**Table 3**). The
 292 reduced end-group mobility of fluorinated polymers in CDCl₃ containing PFH was translated
 293 into higher encapsulation efficiencies. Altogether, these results evidence the ability of
 294 fluorinated polymers to interact with the fluorocarbon phase and enhance its stabilization
 295 inside the organic phase, as previously reported for nanocapsules ¹⁴. For microcapsules
 296 prepared in CH₂Cl₂, no trend was observed for the encapsulation efficiency, probably due the
 297 absence of specific interactions between PFH and the polymer (Table 2).


298 Nonetheless, PLA or PLGA polymers are able to encapsulate higher amounts of PFH into
 299 MCs (~40%) ¹³, the discrepancy with our results may be related to the fast process of solvent

300 evaporation employed here, whereas Mousnier et al. have evaporated the organic solvent
301 slowly at ambient pressure¹³.

302 Although all samples were predominately smooth as shown by SEM in **Figures 3 and**
303 **4 (bottom)**, a certain amount of rough shelled MCs were also observed in all images.
304 According to Chung, *et al.*, this morphological variation might be related to the fast
305 evaporation process used, which promoted an uneven polymer concentration gradient
306 towards the interface⁴¹. Also, a partial PFH vaporization during the solvent evaporation step
307 (performed at 30 °C) may have caused a volumetric expansion of the MCs and, as the
308 temperature dropped, a subsequent shrinkage altered the continuous spreading of the
309 polymer at the interface as previously reported by Lebeveda *et al.* for PFH containing
310 microspheres⁴².



312 **Figure 3.** Confocal (top) and scanning electron microscopy (bottom) images of
313 microcapsules produced in chloroform. Scale bar represents 10 µm.




315 **Figure 4.** Confocal (top) and scanning electron microscopy (bottom) images of
316 microcapsules produced in dichloromethane. Scale bar represents 10 µm.

317 A clear and subtle distinction on MC morphology was observed according to the fluorinated
318 end-group length in both solvents. In all cases, PLA-C₆H₁₃, PLA-C₃F₇ and PLA-C₆F₁₃
319 exhibited core-shell morphologies comprising a well-centered PFH phase; however, as the
320 end-group length increased to C₈F₁₇, C₁₁F₂₃ and C₁₃F₂₇ higher extents of randomly distributed
321 PFH cores were observed as displayed by the white arrows in **Figures 3 and 4 (top)**. In
322 CH₂Cl₂, MCs still possess a distinctive core shell structure but the inner PFH core is
323 displaced from the center of the MC. Such decentered morphology had already been
324 observed¹³. Formulation in CHCl₃ leads to a mixture of structure with well centered MC and
325 with MC having multi-cores of PFH.

326 Regardless of the solvent employed, samples prepared with short fluorinated or non-
327 fluorinated end-groups, PLA-C₃F₇ and PLA-C₆F₁₃ or PLA-C₆H₁₃, presented the formation of
328 core-shell capsules. Only MCs formulated with longer fluorinated groups, PLA-C₈F₁₇, PLA-
329 C₁₁F₂₃ and PLA-C₁₃F₂₇, led to the appearance of different morphologies, either in chloroform
330 or dichloromethane, indicating that the shell precipitates prior to complete PFH nucleation at
331 the center of the organic droplet. Thus, the length of the fluorinated end-group played an
332 important role in the fluorocarbon nucleation process, suggesting that longer fluorous chains
333 were able to better interact and restrain the PFH diffusion as illustrated in **Figure 5**.

334



336

337 **Figure 5.** Schematic representation of the perfluorohexane phase-separation and nucleation
 338 process in the organic phase containing fluorinated polymers of distinct end-group lengths.

339 The different morphologies generated in each solvent are possibly related with the extent of
 340 fluorous interactions, PFH miscibility as well as solvent evaporation rate. In dichloromethane,
 341 the formation of decentered capsules for the longer F-units samples, such as PLA-C₁₃F₂₇,
 342 probably reflected the reduced extent of interactions between the end-groups and PFH.
 343 Nonetheless, such samples were still able to alter the nucleation pattern, inducing the PFH to
 344 accumulate towards the drop's periphery, also suggesting the fluorinated segregation effect.
 345 The obtained decentered morphologies are, however, favored by the solvent's lower boiling
 346 point (39.6 °C for CH₂Cl₂ vs. 61.2 °C for CHCl₃) that accelerates the onset of polymer
 347 precipitation.


348 In chloroform, the shell of polymers with longer fluorinated groups precipitates before the
 349 complete fluorocarbon nucleation restraining PFH diffusion and causes multiple PFH cores
 350 dispersed inside the rigid polymeric phase. As disclosed by T₂ results, the PFH is able to
 351 interact more efficiently with the fluorinated end-groups in this solvent. Thus, such structure

352 is probably attributable to formation of F-rich domains driven by the end-group polymer
353 arrangement to minimize contact with the surrounding polymer. This effect indicates that
354 longer fluorinated units interact more importantly with PFH.

355 **3.3 Influence of polymer concentration on MC morphology**

356 To further evaluate the end-group chemistry and length influence on microcapsules structure,
357 samples PLA-C₆H₁₃, PLA-C₃F₇, PLA-C₈F₁₇ and PLA-C₁₃F₂₇ were prepared only in chloroform
358 using different polymer masses (12.5, 25, 50 and 100 mg) and constant PFH volume of 30
359 μ L.

360 Samples prepared with 12.5 mg presented core-shell structures with thin and smooth
361 polymer layers that were predominant for all polymers, independently of end-group chemistry
362 or length as shown in **Figure 6**. The increase of polymer mass to 25 mg altered only the
363 morphology of MCs having the longest fluorinated group: PLA-C₁₃F₂₇ by formation of
364 multinucleated capsules (42 \pm 10%) as displayed by the white arrow in **Figure 6**. The
365 percentage of multiple PFH cores for PLA-C₁₃F₂₇ became more obvious for 50 and 100 mg,
366 in which the total amount of multinucleated MCs increased from 60 \pm 5% to 91 \pm 3%,
367 respectively. The same effect but at a lower extent was observed for PLA-C₈F₁₇, as thin-
368 shelled MCs are observed in the formulations containing 25 mg and multinucleated
369 morphologies increased from 10 \pm 2% to 56 \pm 7% for 50 and 100 mg, respectively. A similar
370 behavior was observed for MC formulated with the polymer containing the shortest fluorine
371 end-group, PLA-C₃F₇, as core-shell structures predominated until a polymer mass of 100 mg,
372 in which a total of 45 \pm 5% of multinucleated MC were found. In contrast, MC formulated with
373 the non-fluorinated sample, PLA-C₆H₁₃, exhibited core-shell morphologies for all of the tested
374 polymer masses.



375

376 **Figure 6.** Confocal microscopy images of microcapsules formulated in chloroform with non-
 377 fluorinated (PLA-C₆H₁₃) and fluorinated (PLA-C₃F₇, PLA-C₈F₁₇ and PLA-C₁₃F₂₇) polymers with
 378 varied polymer masses: 100, 50, 25 and 12.5 mg. Scale bar of 10 μm.

379 Despite heterogeneity of morphology within the same sample, a clear effect of the polymer
 380 end-group chemistry and fluorinated length was evidenced in the capsule's morphology.
 381 Compared to PLA-C₆H₁₃, polymers containing F-groups generated MCs with decentered
 382 and/or multiple PFH cores. At high fluorinated polymer mass, the dominant morphology
 383 whatever the fluorinated length block consists in multinucleated capsules. This increase in
 384 polymer mass favored the formation of richer fluorophilic domains – in the order of
 385 C₃F₇<C₈F₁₇<C₁₃F₂₇ – that altered the polymeric phase dynamics, reducing the migration of
 386 PFH to the center of the organic drop.

387 **4. Conclusion**

388 We have successfully synthesized and characterized poly(lactide) end-group fluorinated
 389 polymers for improved fluorous interaction with PFH. The presence of fluorinated end-groups

390 provided more favorable interfaces with perfluorohexane in organic solution of chloroform
391 with fluorinated end-group length dependency, as revealed by spin-spin relaxation
392 measurements. The formation of fluorophilic environment is reflected with improved
393 perfluorohexane encapsulation efficiencies into microcapsules and by modifying the final
394 morphology, particularly in the case of longer fluorinated end-groups and important polymer
395 masses.

396

397 **5. Acknowledgements**

398 This work has been supported by the Région Ile-de-France in the framework of DIM Nano-K
399 and the French National Research Agency (ANR) under grant ANR-10-NANO-06 as part of
400 the “Investissements d’Avenir” program. Institut Galien Paris-Sud is a member of the
401 Laboratory of Excellence LERMIT supported by a grant from ANR (ANR-10-LABX-33). We
402 are also thankful to Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
403 for the financial support, to Valerie Nicolas from MIPSIT for helping with confocal
404 experiments, to Prof. Jaísa Soares as well as Prof. Jens Dittmer for their help with NMR
405 relaxation experiments and to Carine Van-Heijenoort, Christina Sizun and Marc-André
406 Delsuc for fruitful discussions.

407

408 **Supporting Information.**

409 ^1H and ^{19}F -NMR spectra of all synthesized polymers in CDCl_3 .

410 SEC chromatogram of all polymers in chloroform at 30°C .

411 Number-average molar masses (M_n) obtained by SEC/ ^1H -NMR, dispersity and glass-
412 transition temperature (T_g) of all polymers.

413 Spin-lattice relaxation (T1) values of correspondent ¹⁹F resonances for samples dissolved in
414 CDCl₃ and CD₂Cl₂ with and without perfluorohexane.

415

416 **References**

- 417 (1) Krafft, M. P.; Riess, J. G. Perfluorocarbons: Life Sciences and Biomedical Uses -
418 Dedicated to the Memory of Professor Guy Ourisson, a True RENAISSANCE Man. *J.*
419 *Polym. Sci. Part a-Polymer Chem.* **2007**, *45* (7), 1185–1198.
420 <https://doi.org/10.1002/pola.21937>.
- 421 (2) Krafft, M. P.; Riess, J. G. Chemistry, Physical Chemistry, and Uses of Molecular
422 Fluorocarbon-Hydrocarbon Diblocks, Triblocks, and Related Compounds-Unique
423 “Apblar” Components for Self-Assembled Colloid and Interface Engineering. *Chem.*
424 *Rev.* **2009**, *109* (5), 1714–1792. <https://doi.org/10.1021/cr800260k>.
- 425 (3) Shaffer, T. H.; Foust, R.; Wolfson, M. R.; Miller, T. F. Analysis of Perfluorochemical
426 Elimination from the Respiratory System. *J. Appl. Physiol.* **1997**, *83* (3), 1033–1033.
427 <https://doi.org/10.1152/jappl.1997.83.3.1033>.
- 428 (4) Cosco, D.; Fattal, E.; Fresta, M.; Tsapis, N. Perfluorocarbon-Loaded Micro and
429 Nanosystems for Medical Imaging: A State of the Art. *J. Fluor. Chem.* **2015**, *171*.
430 <https://doi.org/10.1016/j.jfluchem.2014.10.013>.
- 431 (5) Pisani, E.; Tsapis, N.; Galaz, B.; Santin, M.; Berti, R.; Taulier, N.; Kurtisovski, E.;
432 Lucidarme, O.; Ourevitch, M.; Doan, B. T.; et al. Perfluorooctyl Bromide Polymeric
433 Capsules as Dual Contrast Agents for Ultrasonography and Magnetic Resonance
434 Imaging. *Adv. Funct. Mater.* **2008**, *18* (19). <https://doi.org/10.1002/adfm.200800454>.
- 435 (6) Jafari, S.; Diou, O.; Mamou, J.; Renault, G.; Fattal, E.; Tsapis, N.; Bridal Lori, S. High-
436 Frequency (20 to 40 MHz) Acoustic Response of Liquid-Filled Nanocapsules. *IEEE*
437 *Trans. Ultrason. Ferroelectr. Freq. Control* **2014**, *61* (1).
438 <https://doi.org/10.1109/TUFFC.2014.6689771>.

- 439 (7) Diou, O.; Tsapis, N.; Giraudeau, C.; Valette, J.; Gueutin, C.; Bourasset, F.; Zanna, S.;
440 Vauthier, C.; Fattal, E. Long-Circulating Perfluorooctyl Bromide Nanocapsules for
441 Tumor Imaging by (FMRI)-F-19. *Biomaterials* **2012**, *33* (22), 5593–5602.
442 <https://doi.org/10.1016/j.biomaterials.2012.04.037>.
- 443 (8) Boissenot, T.; Fattal, E.; Bordat, A.; Houvenagel, S.; Valette, J.; Chacun, H.; Gueutin,
444 C.; Tsapis, N. Paclitaxel-Loaded PEGylated Nanocapsules of Perfluorooctyl Bromide
445 as Theranostic Agents. *Eur. J. Pharm. Biopharm.* **2016**, *108*, 136–144.
446 <https://doi.org/10.1016/j.ejpb.2016.08.017>.
- 447 (9) Boissenot, T.; Bordat, A.; Larrat, B.; Varna, M.; Chacun, H.; Paci, A.; Poinignon, V.;
448 Fattal, E.; Tsapis, N. Ultrasound-Induced Mild Hyperthermia Improves the Anticancer
449 Efficacy of Both Taxol® and Paclitaxel-Loaded Nanocapsules. *J. Control. Release*
450 **2017**, *264*. <https://doi.org/10.1016/j.jconrel.2017.08.041>.
- 451 (10) Singh, R.; Husseini, G. A.; Pitt, W. G. Phase Transitions of Nanoemulsions Using
452 Ultrasound: Experimental Observations. *Ultrason. Sonochem.* **2012**, *19* (5), 1120–
453 1125. <https://doi.org/10.1016/J.ULTSONCH.2012.02.005>.
- 454 (11) Li, H.; Wang, J.; Wang, P.; Zheng, J.; Song, F.; Yin, T.; Zhou, G.; Zheng, R.; Zhang,
455 C. Phase-Transition Contrast Nanocapsules Triggered by Low-Intensity Ultrasound.
456 *Chem. Commun.* **2014**, *50* (96), 15163–15166. <https://doi.org/10.1039/C4CC04641B>.
- 457 (12) You, Y.; Wang, Z.; Ran, H.; Zheng, Y.; Wang, D.; Xu, J.; Wang, Z.; Chen, Y.; Li, P.
458 Nanoparticle-Enhanced Synergistic HIFU Ablation and Transarterial
459 Chemoembolization for Efficient Cancer Therapy. *Nanoscale* **2016**, *8* (7), 4324–4339.
460 <https://doi.org/10.1039/C5NR08292G>.
- 461 (13) Mousnier, L.; Huang, N.; Morvan, E.; Fattal, E.; Tsapis, N. Influence of Polymer End-
462 Chemistry on the Morphology of Perfluorohexane Polymeric Microcapsules Intended
463 as Ultrasound Contrast Agents. *Int. J. Pharm.* **2014**, *471* (1–2).
464 <https://doi.org/10.1016/j.ijpharm.2014.05.012>.
- 465 (14) Picheth, G.; Houvenagel, S.; Dejean, C.; Couture, O.; Alves de Freitas, R.; Moine, L.;
466 Tsapis, N. Echogenicity Enhancement by End-Fluorinated Polylactide

- 467 Perfluorohexane Nanocapsules: Towards Ultrasound-Activable Nanosystems. *Acta*
468 *Biomater.* **2017**, *64*. <https://doi.org/10.1016/j.actbio.2017.10.002>.
- 469 (15) Astafyeva, K.; Somaglino, L.; Desgranges, S.; Berti, R.; Patinote, C.; Langevin, D.;
470 Lazeyras, F.; Salomir, R.; Polidori, A.; Contino-Pépin, C.; et al. Perfluorocarbon
471 Nanodroplets Stabilized by Fluorinated Surfactants: Characterization and Potentiality
472 as Theranostic Agents. *J. Mater. Chem. B* **2015**, *3* (14), 2892–2907.
473 <https://doi.org/10.1039/C4TB01578A>.
- 474 (16) Fernandes, D. A.; Fernandes, D. D.; Li, Y.; Wang, Y.; Zhang, Z.; Rousseau, D.;
475 Gradinaru, C. C.; Kolios, M. C. Synthesis of Stable Multifunctional Perfluorocarbon
476 Nanoemulsions for Cancer Therapy and Imaging. *Langmuir* **2016**, *32* (42), 10870–
477 10880. <https://doi.org/10.1021/acs.langmuir.6b01867>.
- 478 (17) Oda, Y.; Suzuki, R.; Mori, T.; Takahashi, H.; Natsugari, H.; Omata, D.; Unga, J.;
479 Uruga, H.; Sugii, M.; Kawakami, S.; et al. Development of Fluorous Lipid-Based
480 Nanobubbles for Efficiently Containing Perfluoropropane. *Int. J. Pharm.* **2015**, *487* (1–
481 2), 64–71. <https://doi.org/10.1016/J.IJPHARM.2015.03.073>.
- 482 (18) Koda, Y.; Terashima, T.; Sawamoto, M. Fluorinated Microgel Star Polymers as
483 Fluorous Nanocapsules for the Encapsulation and Release of Perfluorinated
484 Compounds. *Polym. Chem.* **2015**, *6* (31), 5663–5674.
485 <https://doi.org/10.1039/c5py00113g>.
- 486 (19) Houvenagel, S.; Picheth, G.; Dejean, C.; Brulet, A.; Chenneviere, A.; Couture, O.;
487 Huang, N.; Moine, L.; Tsapis, N. End-Chain Fluorination of Polyesters Favors
488 Perfluorooctyl Bromide Encapsulation into Echogenic PEGylated Nanocapsules.
489 *Polym. Chem.* **2017**, *8* (16), 2559–2570. <https://doi.org/10.1039/C7PY00400A>.
- 490 (20) Houvenagel, S.; Moine, L.; Picheth, G.; Dejean, C.; Brûlet, A.; Chennevière, A.;
491 Faugeras, V.; Huang, N.; Couture, O.; Tsapis, N. Comb-Like Fluorophilic-Lipophilic-
492 Hydrophilic Polymers for Nanocapsules as Ultrasound Contrast Agents.
493 *Biomacromolecules* **2018**, *19* (8), 3244–3256.
494 <https://doi.org/10.1021/acs.biomac.8b00506>.

- 495 (21) Kaberov, L. I.; Verbraeken, B.; Hruby, M.; Riabtseva, A.; Kovacic, L.; Kereïche, S.;
496 Brus, J.; Stepanek, P.; Hoogenboom, R.; Filippov, S. K. Novel Triphilic Block
497 Copolymers Based on Poly(2-Methyl-2-Oxazoline)– Block –poly(2-Octyl-2-Oxazoline)
498 with Different Terminal Perfluoroalkyl Fragments: Synthesis and Self-Assembly
499 Behaviour. *Eur. Polym. J.* **2017**, *88*, 645–655.
500 <https://doi.org/10.1016/j.eurpolymj.2016.10.016>.
- 501 (22) Kaberov, L. I.; Verbraeken, B.; Riabtseva, A.; Brus, J.; Talmon, Y.; Stepanek, P.;
502 Hoogenboom, R.; Filippov, S. K. Fluorinated 2-Alkyl-2-Oxazolines of High Reactivity:
503 Spacer-Length-Induced Acceleration for Cationic Ring-Opening Polymerization As a
504 Basis for Triphilic Block Copolymer Synthesis. *ACS Macro Lett.* **2018**, *7* (1), 7–10.
505 <https://doi.org/10.1021/acsmacrolett.7b00954>.
- 506 (23) Riabtseva, A.; Kaberov, L. I.; Noirez, L.; Ryukhtin, V.; Nardin, C.; Verbraeken, B.;
507 Hoogenboom, R.; Stepanek, P.; Filippov, S. K. Structural Characterization of
508 Nanoparticles Formed by Fluorinated Poly(2-Oxazoline)-Based Polyphiles. *Eur.*
509 *Polym. J.* **2018**, *99*, 518–527. <https://doi.org/10.1016/J.EURPOLYMJ.2018.01.007>.
- 510 (24) Kaberov, L. I.; Verbraeken, B.; Riabtseva, A.; Brus, J.; Radulescu, A.; Talmon, Y.;
511 Stepanek, P.; Hoogenboom, R.; Filippov, S. K. Fluorophilic–Lipophilic–Hydrophilic
512 Poly(2-Oxazoline) Block Copolymers as MRI Contrast Agents: From Synthesis to Self-
513 Assembly. *Macromolecules* **2018**, *51* (15), 6047–6056.
514 <https://doi.org/10.1021/acs.macromol.8b00957>.
- 515 (25) Horváth, I. T. Fluorous Biphasic Chemistry. *Acc. Chem. Res.* **1998**, *31* (10), 641–650.
516 <https://doi.org/10.1021/ar970342i>.
- 517 (26) Koda, Y.; Terashima, T.; Sawamoto, M.; Maynard, H. D. Amphiphilic/Fluorous
518 Random Copolymers as a New Class of Non-Cytotoxic Polymeric Materials for Protein
519 Conjugation. *Polym. Chem.* **2015**, *6*, 240–247. <https://doi.org/10.1039/C4PY01346H>.
- 520 (27) Singh, A.; Naskar, A. K.; Haynes, D.; Drews, M. J.; Smith, D. W. Synthesis,
521 Characterization and Surface Properties of Poly(Lactic Acid)-Perfluoropolyether Block
522 Copolymers. *Polym. Int.* **2011**, *60* (3), 507–516. <https://doi.org/10.1002/pi.2982>.

- 523 (28) Giuntoli, G.; Rosi, L.; Frediani, M.; Sacchi, B.; Frediani, P. Fluoro-Functionalized PLA
524 Polymers as Potential Water-Repellent Coating Materials for Protection of Stone. *J.*
525 *Appl. Polym. Sci.* **2012**, *125* (4), 3125–3133. <https://doi.org/10.1002/app.36469>.
- 526 (29) Diou, O.; Fattal, E.; Delplace, V.; Mackiewicz, N.; Nicolas, J.; Mériaux, S.; Valette, J.;
527 Robic, C.; Tsapis, N. RGD Decoration of PEGylated Polyester Nanocapsules of
528 Perfluorooctyl Bromide for Tumor Imaging: Influence of Pre or Post-Functionalization
529 on Capsule Morphology. *Eur. J. Pharm. Biopharm.* **2014**, *87* (1), 170–177.
530 <https://doi.org/10.1016/j.ejpb.2013.12.003>.
- 531 (30) Aguilar, J. A.; Nilsson, M.; Bodenhausen, G.; Morris, G. A. Spin Echo NMR Spectra
532 without J Modulation. *Chem. Commun.* **2012**, *48* (6), 811–813.
533 <https://doi.org/10.1039/C1CC16699A>.
- 534 (31) Henderson, T. J. Quantitative NMR Spectroscopy Using Coaxial Inserts Containing a
535 Reference Standard: Purity Determinations for Military Nerve Agents. *Anal. Chem.*
536 **2002**, *74* (1), 191–198. <https://doi.org/10.1021/ac010809+>.
- 537 (32) Böhmer, M. R.; Schroeders, R.; Steenbakkens, J. A. M.; de Winter, S. H. P. M.;
538 Duineveld, P. A.; Lub, J.; Nijssen, W. P. M.; Pikkemaat, J. A.; Stapert, H. R.
539 Preparation of Monodisperse Polymer Particles and Capsules by Ink-Jet Printing.
540 *Colloids Surfaces A Physicochem. Eng. Asp.* **2006**, *289* (1–3), 96–104.
541 <https://doi.org/10.1016/J.COLSURFA.2006.04.011>.
- 542 (33) Agrawal, A.; Saran, A. D.; Rath, S. S.; Khanna, A. Constrained Nonlinear Optimization
543 for Solubility Parameters of Poly(Lactic Acid) and Poly(Glycolic Acid) - Validation and
544 Comparison. *Polymer (Guildf).* **2004**, *45* (25), 8603–8612.
545 <https://doi.org/10.1016/j.polymer.2004.10.022>.
- 546 (34) Foster, T.; Dorfman, K. D.; Ted Davis, H. Giant Biocompatible and Biodegradable
547 PEG–PMCL Vesicles and Microcapsules by Solvent Evaporation from Double
548 Emulsion Droplets. *J. Colloid Interface Sci.* **2010**, *351* (1), 140–150.
549 <https://doi.org/10.1016/J.JCIS.2010.05.020>.
- 550 (35) Berger, R.; Resnati, G.; Metrangolo, P.; Weber, E.; Hulliger, J. Organic Fluorine

551 Compounds: A Great Opportunity for Enhanced Materials Properties. *Chem. Soc.*
552 *Rev.* **2011**, *40* (7), 3496. <https://doi.org/10.1039/c0cs00221f>.

553 (36) Ojogun, V.; Knutson, B. L.; Vyas, S.; Lehmler, H.-J. Fluorophilicity of Alkyl and
554 Polyfluoroalkyl Nicotinic Acid Ester Prodrugs. *J. Fluor. Chem.* **2010**, *131* (7), 784–790.
555 <https://doi.org/10.1016/J.JFLUCHEM.2010.04.001>.

556 (37) Shen, J.; Piunova, V. A.; Nutt, S.; Hogen-Esch, T. E. Blends of Polystyrene and
557 Poly(n-Butyl Methacrylate) Mediated by Perfluorocarbon End Groups. *Polymer*
558 *(Guildf)*. **2013**, *54* (21), 5790–5800. <https://doi.org/10.1016/J.POLYMER.2013.08.059>.

559 (38) Marchione, A. A.; Buck, R. C. Complete Multinuclear Magnetic Resonance
560 Characterization of a Set of Polyfluorinated Acids and Alcohols. *Magn. Reson. Chem.*
561 **2009**, *47* (2), 194–198. <https://doi.org/10.1002/mrc.2376>.

562 (39) Twum, E. B.; Gao, C.; Li, X.; McCord, E. F.; Fox, P. A.; Lyons, D. F.; Rinaldi, P. L.
563 Characterization of the Chain-Ends and Branching Structures in Polyvinylidene
564 Fluoride with Multidimensional NMR. *Macromolecules* **2012**, *45* (13), 5501–5512.
565 <https://doi.org/10.1021/ma300835s>.

566 (40) Kadayakkara, D. K.; Damodaran, K.; Hitchens, T. K.; Bulte, J. W. M.; Ahrens, E. T.
567 ¹⁹F Spin–lattice Relaxation of Perfluoropolyethers: Dependence on Temperature and
568 Magnetic Field Strength (7.0–14.1 T). *J. Magn. Reson.* **2014**, *242*, 18–22.
569 <https://doi.org/10.1016/J.JMR.2014.01.014>.

570 (41) Chung, T.-W.; Huang, Y.-Y.; Liu, Y.-Z. Effects of the Rate of Solvent Evaporation on
571 the Characteristics of Drug Loaded PLLA and PDLLA Microspheres. *Int. J. Pharm.*
572 **2001**, *212* (2), 161–169. [https://doi.org/10.1016/S0378-5173\(00\)00574-3](https://doi.org/10.1016/S0378-5173(00)00574-3).

573 (42) Lebedeva, N. V.; Sanders, S. N.; Ina, M.; Zhushma, A. P.; Olson, S. D.; Rubinstein,
574 M.; Sheiko, S. S. Multicore Expandable Microbubbles: Controlling Density and
575 Expansion Temperature. *Polymer (Guildf)*. **2016**, *90*, 45–52.
576 <https://doi.org/10.1016/J.POLYMER.2016.02.050>.

577